Vancouver, British Columbia--(Newsfile Corp. - March 25, 2026) - Bell Copper Corporation (TSXV: BCU) (OTCQB: BCUFF) ("Bell Copper" or the "Company") announces, further to its news release of March 6, 2026 regarding a non-brokered financing ("Financing") of $2,052,000 secured 10% convertible debentures (the "Debentures") arranged through Crescat Portfolio Management LLC and/or its nominees ("Crescat"), that the conversion price of the Debentures into common share of the Company ("Shares") during the first y ...

Core Viewpoint - Telo Genomics Corp. has successfully closed the first tranche of a non-brokered private placement offering, raising gross proceeds of $840,000 through the issuance of secured convertible debentures [1][2]. Financing Details - The debentures carry an interest rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026. Holders can convert the principal amount into common shares at a conversion price of $0.05 per share before maturity [2]. - In connection with the sale of the debentures, Telo Genomics issued a total of 16,800,000 detachable warrants, each exercisable at an exercise price of $0.08 per share until February 17, 2027 [3]. - The proceeds from the offering are intended for lab trials and general working capital, with cash finder's fees of $58,800 paid and 1,176,000 finder's warrants issued, also exercisable at $0.08 per share until February 17, 2028 [4]. Regulatory and Compliance - The offering is subject to conditions, including necessary approvals from the TSX Venture Exchange, and the securities issued will be subject to a hold period expiring on June 18, 2026, in accordance with Canadian securities laws [5]. Company Overview - Telo Genomics is a biotech company focused on developing diagnostic and prognostic tests through chromosomal telomere analysis, with applications in oncology and neurological diseases. The company emphasizes the advantages of liquid biopsies, which are less invasive and more replicable than traditional methods [6]. - The company's proprietary technology has been validated in over 160 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients with various cancers and Alzheimer's disease. Its lead application, Telo-MM, aims to provide critical information for treating Multiple Myeloma [6].

Core Viewpoint - Canadian Net Real Estate Investment Trust has successfully closed a non-brokered private placement of unsecured convertible debentures amounting to $4.0 million, aimed at supporting its growth and financial flexibility [1][2][5]. Group 1: Private Placement Details - The private placement involved the issuance of $4.0 million in principal amount of convertible debentures, which will mature on December 1, 2030, and bear an annual interest rate of 7.0% payable semi-annually [2]. - The convertible debentures are convertible into units of Canadian Net at a conversion price of $6.75 per unit, with the company having the right to redeem them after December 1, 2028, if certain market conditions are met [2][3]. Group 2: Use of Proceeds - The net proceeds from the private placement will be allocated for acquisitions, repayment of outstanding indebtedness, transaction costs, and general working capital purposes [4]. Group 3: Company Background - Canadian Net Real Estate Investment Trust is an open-ended trust focused on acquiring and owning high-quality triple net and management-free commercial real estate properties [6].

Core Viewpoint - Alaris Equity Partners Income Trust has increased the size of its bought deal financing due to excess demand, now issuing 80,000 convertible unsecured senior debentures for total gross proceeds of $80 million [1]. Group 1: Financing Details - The offering consists of 80,000 convertible unsecured senior debentures priced at $1,000 each, totaling $80 million in gross proceeds [1]. - An additional option for underwriters to purchase up to $12 million in debentures is available, exercisable within 30 days post-closing [1]. - The offering is expected to close around June 2, 2025, pending necessary corporate and regulatory approvals [2]. Group 2: Company Overview - Alaris invests in a diversified group of private businesses primarily through structured equity, aiming to deliver stable returns to unitholders via cash distributions and capital appreciation [4].